Emerald Investment Advisers LLC bought a new stake in Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 55,631 shares of the company's stock, valued at approximately $2,167,000. Emerald Investment Advisers LLC owned approximately 0.09% of Kodiak Sciences as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. AQR Capital Management LLC purchased a new position in shares of Kodiak Sciences in the first quarter worth about $188,000. Dynamic Technology Lab Private Ltd bought a new position in Kodiak Sciences during the first quarter valued at approximately $94,000. Jane Street Group LLC grew its holdings in shares of Kodiak Sciences by 441.3% in the first quarter. Jane Street Group LLC now owns 64,649 shares of the company's stock worth $181,000 after purchasing an additional 52,705 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Kodiak Sciences by 6.3% during the second quarter. American Century Companies Inc. now owns 79,745 shares of the company's stock valued at $297,000 after acquiring an additional 4,703 shares during the last quarter. Finally, Federated Hermes Inc. raised its holdings in Kodiak Sciences by 190.7% in the 2nd quarter. Federated Hermes Inc. now owns 244,231 shares of the company's stock worth $911,000 after purchasing an additional 160,225 shares in the last quarter. 89.06% of the stock is owned by institutional investors.
Kodiak Sciences Stock Performance
Shares of KOD opened at $38.33 on Friday. The company's fifty day moving average is $39.90 and its 200 day moving average is $35.47. The stock has a market capitalization of $2.41 billion, a PE ratio of -9.15 and a beta of 2.21. Kodiak Sciences Inc. has a fifty-two week low of $8.29 and a fifty-two week high of $47.84.
Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.96) by ($0.09). As a group, research analysts forecast that Kodiak Sciences Inc. will post -3.83 earnings per share for the current year.
Wall Street Analyst Weigh In
KOD has been the subject of a number of analyst reports. Wall Street Zen lowered Kodiak Sciences from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Chardan Capital upgraded shares of Kodiak Sciences from a "neutral" rating to a "buy" rating and raised their target price for the stock from $14.00 to $61.00 in a report on Monday, May 11th. HC Wainwright restated a "buy" rating and set a $58.00 price target on shares of Kodiak Sciences in a research note on Monday, August 17th. JPMorgan Chase & Co. raised their target price on Kodiak Sciences from $56.00 to $66.00 and gave the stock an "overweight" rating in a report on Monday, August 3rd. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Kodiak Sciences in a report on Friday, July 10th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $48.14.
View Our Latest Analysis on Kodiak Sciences
Kodiak Sciences Company Profile
(
Free Report)
Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.
The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Kodiak Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kodiak Sciences wasn't on the list.
While Kodiak Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
